Warning Letter — giantnic.com
The FDA Center for Tobacco Products issued a warning letter to giantnic.com on August 7, 2026, regarding compliance issues with tobacco product regulations. The source provides the formal issuance notice and the recipient's domain name.
This notice affects the operator of giantnic.com and potentially other online tobacco retailers, as well as regulatory and compliance functions managing nicotine product distribution.
The issuance of a warning letter by the Center for Tobacco Products (CTP) indicates that the FDA has identified specific violations regarding the sale or distribution of tobacco products. This suggests increased surveillance of online retailers to ensure that all products offered for sale meet federal regulatory requirements, including necessary marketing authorizations.
E-commerce platforms selling tobacco products should audit their product listings for valid marketing authorizations and ensure immediate removal of any products identified in FDA warning letters. Regulatory teams should review local and federal compliance requirements for online nicotine distribution.
FDA Warning Letter issued to: giantnic.com. 08/07/2026 — Center for Tobacco Products. Source: https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/giantniccom-735905-08072026
Open in openFDA / FDA.gov